This chapter aligns with Goal 14: Life Below Water and Goal 3: Good Health and Wellbeing by highlighting some of the many beneficial pharmaceutical applications of marine algae bromophenols.
Elsevier,
Current Trends and Future Developments on (Bio-) Membranes: Membrane Technologies in Environmental Protection and Public Health: Challenges and Opportunities, Volume 1, 1 January 2022
This chapter aligns with Goal 3: Good health and well-being and Goal 15: Life on land by summarizing the mechanisms through which different forms of pollution impact human health, with particular emphasis on air, water, soil, and noise pollution.
This content supports the SDG Goal 3: Good health and well-being by exploring the human hepatitis B virus (HBV), family Hepadnaviridae, as a highly infectious virus transmitted by blood and body fluids.
Elsevier,
Smart Nanomaterials to Combat the Spread of Viral Infections
Advanced Strategies for the Prevention of Viral Infections
2023, Pages 97-123
This content supports the SDG Goal 3: Good health and well-being by discussing the role of multifunctional metal nanoparticles as antiviral therapeutic agents and nanovaccines against different viruses, including human immunodeficiency virus, hepatitis viruses, influenza A virus, herpes simplex virus, and severe acute respiratory syndrome coronavirus 2.
Elsevier,
Genomic Data Sharing, Case Studies, Challenges, and Opportunities for Precision Medicine, 2023, Pages 71-90
The Global Alliance for Genomics and Health (GA4GH) is an international standards development organization focused on advancing human health and medicine through genomic data sharing and interoperability. Founded in 2013, the organization has evolved over time and has adapted to unexpected challenges. Three themes have emerged as critical to the organization's success: (1) community needs must drive development; (2) agility is necessary to create global equity and opportunity; (3) developing an idea into a widely adopted standard requires multiple levels of consensus furthering SDG3.
This chapter advances the UN SDG goals 3 and 17 by reviewing the use of cannabidiol oil for AD patients.
This chapter advances the UN SDG goals 3 and 17 discusses the effects COVID had on the lifestyle of patients with AD.
This chapter advances the UN SDG goals 3 and 17 discusses the female gender on AD risk.
This chapter advances the UN SDG goal 3 and 17 by exploring antiogensin in relation to the treatment of neurological disorders
This content aligns with Goal 3: Good Health and Wellbeing by providing a current understanding of the cellular and molecular basis of mammalian antifungal immunity, which shows promise for guiding immunotherapy and vaccination strategies for at-risk patients, including those with HIV/AIDS.
